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Abstract
Recent works have highlighted a double role for the Transforming Growth Factor b (TGF -b): it inhibits cancer in healthy
cells and potentiates tumor progression during late stage of tumorigenicity, respectively; therefore it has been termed the
‘‘Jekyll and Hyde’’ of cancer or, alternatively, an ‘‘excellent servant but a bad master’’. It remains unclear how this molecule
could have the two opposite behaviours. In this work, we propose a TGF -b multi scale mathematical model at molecular,
cellular and tissue scales. The multi scalar behaviours of the TGF -b are described by three coupled models built up together
which can approximatively be related to distinct microscopic, mesoscopic, and macroscopic scales, respectively. We first
model the dynamics of TGF -b at the single-cell level by taking into account the intracellular and extracellular balance and
the autocrine and paracrine behaviour of TGF -b. Then we use the average estimates of the TGF -b from the first model to
understand its dynamics in a model of duct breast tissue. Although the cellular model and the tissue model describe
phenomena at different time scales, their cumulative dynamics explain the changes in the role of TGF -b in the progression
from healthy to pre-tumoral to cancer. We estimate various parameters by using available gene expression datasets. Despite
the fact that our model does not describe an explicit tissue geometry, it provides quantitative inference on the stage and
progression of breast cancer tissue invasion that could be compared with epidemiological data in literature. Finally in the
last model, we investigated the invasion of breast cancer cells in the bone niches and the subsequent disregulation of bone
remodeling processes. The bone model provides an effective description of the bone dynamics in healthy and early stages
cancer conditions and offers an evolutionary ecological perspective of the dynamics of the competition between cancer and
healthy cells.
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Introduction
A full systemic understanding of cancer process will benefit from
investigating cell-tissue interaction. We can observe what happens
at more or less all scales, from the disease at the whole organism
down to the molecular level of cancer, and we have good amount
of experimental data on all levels of biological organization.
However, putting things together in order to obtain real
understanding is much more difficult and much less developed.
A way to build up multi scale models is by using proteins that are:
1) mutational drivers, meaning the mutation of one of the related
genes causes the change of the phenotype, 2) able to interact with
proteins which have intracellular and extracellular effects; hence,
involving multi-cellular phenomena. Here, we start with the
consideration that tissue modeling is the missing link between basic
research and clinical practice, and we aim at using a modeling
approach to bridge the cell to tissue scale in health and disease
(cancer) dynamics. A key player of this multi scale process is TGF -
b family of cytokines that control numerous cellular responses,
including proliferation, differentiation, apoptosis and migration.
TGF -b is always produced as an inactive cytokine that cannot
bind to its receptor and function unless the latent complex is
somehow activated. This regulation provides a complex control of
TGF -b function, thereby ensuring that its potent effects are
produced in appropriate locations and times. TGF -b interacts
with cytoskeleton, epithelial cadherin (E-cad) and integrins
producing a multi scale mechanobiological effects on tissue [1].
Cancer is a multi scale, multifactorial and multi step process [2,3].
The cancer cells undergo a cascade of mutations, some of them
changing the phenotype, to obtain the ability to metastasise, and
are constantly exposed to signals that induce apoptosis. Acquisition
of antiapoptotic properties by cancer cells is important for
metastasis, and recent studies suggest that TGF -b promotes the
survival of certain types of cancer cells [4,5]. TGF -b both inhibits
and facilitates tumor progression during early and late stage of
tumorigenicity, respectively. However, it still remains veiled how
TGF -b plays both contrasting roles [6–8]. Therapies based on
TGF -b seem promising [9]. Tumorigenesis is in many respects a
process of disregulated cellular evolution that drives malignant
cells to acquire several phenotypic hallmarks of cancer, including
the ability of growing autonomously, disregarding cytostatic
signals, ignoring apoptotic signals, stimulating angiogenesis,
invading, metastasising and becoming immortal. In the next
section, we introduce the role of TGF -b in breast cancer.
The Ductal Lobular Unit and Breast Cancer
The terminal ductal lobular unit is the basic functional and
histopathological unit of the breast, and it has been identified as
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the site of origin of the most common breast malignancy. The
ductal carcinoma corresponds to a specific stage of cancer
development of the mammary parenchyma, Figure (1). Recent
works showed that TGF -b is abundantly expressed by highly
metastatic breast cancer cells and promotes their survival. In
particular, TGF -b autocrine signaling, in certain breast cancers,
promotes cell survival via inhibition of apoptotic signaling [10].
Major determinants of the ‘‘tissue identity’’ are the cadherins and
integrins which are adhesion molecules regulating cell-cell and
cell-matrix interactions. Cells containing a specific cadherin
subtype tend to cluster together to the exclusion of other types,
both in cell culture and during development. In vitro and in vivo
studies have demonstrated the existence of crosstalk between
integrins and cadherins in cell adhesion and motility.
Integrins play a key role in activating the latent complex of
TGF -b. The binding of integrins to the latent complex induces a
conformational change that produces active TGF -b that binds to
its receptor. Evidence now points to a crucial role for cell
contraction in the activation of TGF -b via few types of integrins.
An intact actin cytoskeleton is required for TGF -b activation by
these integrins; activation is greatly reduced by treatment of cells
with the actin polymerization inhibitor cytochalasin. Additionally,
treatment of cells with inhibitors of cell contraction, greatly
reduces integrin-mediated TGF -b activation, whereas agents that
stimulate cell contraction, such as thrombin, angiotensin-II and
endothelin-1 enhance TGF -b activation by integrins [1].
In breast cancer, the expression of E-cad is a hallmark of a well
differentiated epithelium that functions to maintain cell-cell
junctions, thereby inhibiting aberrant cell proliferation and
migration. The loss of E-cad function via genetic inactivation by
TGF -b or via epigenetic silencing is a common characteristic of
systemically invasive carcinomas. Down-regulated E-cad expres-
sion is required for the outgrowth of breast cancer cells. Breast
cancer cells show a typical pattern of dissemination by 1) down-
regulating E-cad expression or activity; 2) separating cell-cell
junctions; 3) invading the surrounding tissues; and 4) intravasating
the vasculature or lymphatic system [11]. Recent works show that
down-regulated E-cad expression induced by TGF -b was suffi-
cient to prevent mammary epithelial cell differentiation and
instead, produced dense and more spherical cultures that
underwent metastatic outgrowth [12] [13].
Here, we model the molecular and cellular mechanisms that
underlie the TGF -b capacity in suppressing tumor development in
normal cells, and conversely, to facilitate cancer progression and
increase number of malignant cells. Our multi scale model focuses
on the TGF -b activation requirement, its autocrine properties of
TGF -b, its role in promoting cell contraction and being activated
by cell contraction [6]. First we model the single cell and then the
cell population by investigating the autocrine and paracrine of
TGF -b in a generic epithelial tissue. We investigate the relation
between the concentration of TGF -b and its receptors with respect
to the stage of the cancer. In this perspective, we model the early
invasion of few malignant cells in a healthy tissue and the different
role of autocrine and paracrine TGF -b secretion. The autocrine
and paracrine behaviour are explored on the light of the
evolutionary ecology principle of malignant and healthy cell
competition. It is known that the bone tissue is the preferred niche
of breast cancer colonization; we present a model of the role of
TGF -b in bone invasion and alteration of bone tissue remodeling
dynamics.
In summary, here, we introduce a set of scale specific
mathematical models that render the multi scale behaviours of
TGF -b allowing us to describe the early breast cancer develop-
ment and the initial condition of the metastasisation process by
using a level of description familiar to biologists in order to
encourage experimentation and hypothesis testing.
Results
The development and spread of cancer, although caused by
driver mutations producing variations in gene expression and
signaling disfunctions, involves cytoskeleton biomechanical chang-
es that modulate cell dynamics at the tissue level. The
development of a tissue mathematical model requires considering
the TGF -b autocrine and paracrine behaviour of the cells.
Therefore, we focused on the interface between intracellular and
extracellular compartments. Given the different time dynamics of
the reactions at the intracellular pathways level and the cell
dynamics at tissue levels, we prefer to build distinct models,
coupled by time averages of the fastest dynamics. Following the
model developed by Laise et al. [14], we have focused on
autocriny and paracriny behaviours of the TGF -b. Next, we have
considered a tissue model to describe the effects of the TGF -b on
cellular populations characterized by different driver mutations.
Finally, we consider the bone niche model which allows us to
describe the effects of the tumoral cells on the BMU (Basic
Multicellular Unit) remodeling cycle. Each of these models
describes different aspects of the TGF -b at a particular scale
and they are loosely coupled by using averaged quantities of TGF -
b in such a way to mimic the interactions between different scales;
This allows us to consider each model as a ‘‘sub-model’’ which is
part of a more comprehensive multi scale model. From here on,
when we refer to the multi scale model, we will use the single term
model, and we will specify otherwise when referring to one of the
scale specific model. Describing the dynamic development of
tumors requires the knowledge of numerous degrees of freedom,
which often are not experimentally available, and a complex
model able to correctly analyse all the data, retrieve the relevant
information of the present state and simulate its future evolution.
Here, we propose a model to explain the early stages of tumor and
its evolution in bone tissue based on production and sensing of
TGF -b in both the paracrine and autocrine processes.
The Intracellular Generation of TGF -b Fluxes
In this work, we follow the model of Laise et al. and [15,16] that
for the sake of completeness, we will re-propose and adapt into the
structure and the aims of a multi dimensional model that embrace
both the intracellular/cell and cell/tissue interfaces. They
considered a simple biochemical model which explicitly describe
the key features of the Smad pathway. The first three equations of
the model, see system of equations (1), accounts for the interaction
between TGF -b (bec) and the inactive membrane receptor (Rec).
Following a successful encounter, the receptor turns into its active
form here denoted R?ec. In reality, different isoforms of TGF -b and
of its receptor exist. In [14], the authors simplify the model setting
by considering just one receptor type, which can operate in its
active (bound to TGF -b) or inactive configuration. The activated
receptor is able to phosphorylate the R-Smad proteins (Sc) in the
cytoplasm, resulting in the formation of a new species, the
phosphorylated Smad protein, here labelled pSc. Once phosphor-
ylated, the Smad proteins head towards the nucleus. The
translocation of the Smad proteins into the nucleus (pSn) is
necessary to activate the transcriptional activity. This is a complex
process, possibly organized in cascade regulatory cycles. Note that
cytoplasmatic pSc are modified into nuclear pSn with a rate
specified by the control parameter kin. The presence of
phosphorylated Smad in the nucleus is in turn associated to an
increase of the hmga2 gene expression [17]. The nucleus is also
Modeling TGF-b in Cancer Tissue Dynamics
PLOS ONE | www.plosone.org 2 February 2014 | Volume 9 | Issue 2 | e88533
enriched by phosphates (PPase) targeting phosphorylated Smad
[16]. The dephosphorylation of the nuclear Smad proteins pSn
results in non-phosphorylated nuclear Smad elements Sn. The
model is composed of eight variables, respectively bec, Rec, R
?
ec, Sc,
pSc, pSn, Sn and hmga2. The associated concentrations obey to
the following set of ordinary differential equations:
Lt bec~{rb bec(t) Rec(t),
Lt Rec~{rb bec(t) Rec(t),
Lt R?ec~rb bec(t) Rec(t){kp R
?
ec(t) Sc(t),
ð1Þ
Figure 1. 3D representation of the mammary duct. The mammary duct is formed by epithelial cells. Normal ductal cells (w~0) are regularly
arranged on a single 2-dimensional layer. Tissue irregularities appear in presence of benign ductal cells, but cells still lie on a surface. When epithelial
cells develop an aggressive phenotype (w~3), they begin to stratify.
doi:10.1371/journal.pone.0088533.g001
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Lt Sc~{kp R?ec(t) Sc(t)zkex Sn(t),
Lt pSc~kp R?ec(t) Sc(t){kin pSc(t),
Lt pSn~kin pSc(t){ks pSn(t){kdephos pSn(t) PPase,
Lt Sn~kdephos pSn(t) PPase{kex Sn(t),
Lt hmga2~km pSn(t):
where the notation Lt represents the partial derivative in respect
to the dependent variable t indicating the variation in time of the
following quantity on the right. In the last equation of the system
(1), hmga2 measures the mRNA amount and as such assumes
arbitrary units. All the other concentrations are instead expressed
in nmol. Notice that the concentration of PPase remains
unchanged all along the dynamical evolution. Asymptotically,
the system admits a family of stable fixed points. From the
experimental results in [16], eventually the TGF -b amount as well
as the activated receptors amount go to zero, and consequently,
there is only one fixed point that satisfied such conditions.
Analogously, according to the model specification, we have
bec~R
?
ec~pSc~pSn~Sn~0. The quantities Rec, Sc and
hmga2 converge instead to stationary solutions, function of the
initial condition and of the kinetic parameters involved. The TGF -
b pathway is in particular reduced to a limited set of meaningful
chemical reactions that are presumably implicated in the
transmission of the signal from the cell surface, as triggered by
TGF -b, to the cell nucleus. The analysis conducted by the authors
in [14] is in particular aimed at inspecting the out-of-equilibrium
dynamics of the system, as driven by the externally imposed TGF -
b. The model proposed by Laise et al. for the epithelial-
mesenchymal transition predicts the concentration of mRNA
associated to gene hmga2, properly describes the results of the in-
vitro experiments set up by [16] and reproduces the right
unperturbed steady state characterized by specific concentrations
of cytoplasmatic Smad proteins Sc and unbound receptors Rec,
which have been carefully evaluated by Schmierer and collabo-
rators.
To address the problem of building a model which takes into
consideration the effects of the TGF -b pathway signaling and
tumor regulation at different scales, we adopt this intracellular
model as a starting point. In our multi scale approach, we
introduce two main re-adaptation of the previous intracellular
model. First, we have done a model order reduction regarding the
Smad and the hmga2 concentrations by imposing kp Sc constant
in time, which allows us to simplify the intracellular processes
disregarding the effect of the Smad signaling cascade reactions, see
equations (1) in the dashed line box, in order to focus on the TGF -
b pathway, see equations (1) in the continuous line box. The
justification for such approximation, as explained in [14], is due to
the large amount of Sc in comparison to R
?
ec and to the re-
integration of Sc which permits us to consider the variation of the
Smad in the cytoplasm negligible. Second, for a description of
processes that occur not only at different spatial scales, but also at
different time scales, we need to introduce source terms (and sink
terms when necessary) for the synthesis of both the TGF -b and its
receptors in order to move the fixed point in such a way the
remaining quantities, at intracellular scale, are all different from
zero. This is much more reasonable for long and continuously
ongoing processes; while positive quantities, like the concentra-
tions, approaching zero implies the processes will come to a
standstill irremediably affecting the system at all scales.
The Cellular Model
The cellular model is the first of the three models where we
discuss the intracellular/cell interface and take into consideration
the dynamic effects of the TGF -b in a small patch of cells. With
this model, we address the problem of production and internal-
ization of TGF -b along with the binding of autocrine or paracrine
TGF -b to the receptors on the membranes without considering
the detailed spatial disposition of cells. Even though the autocrine
and paracrine signaling are completely distinct forms of exchang-
ing chemicals, it is impossible to distinguish between the two when
they occur at the same time. It is true that a cell can sense the local
spatial inhomogeneity of chemicals and the heterogeneity of and
positions of other cells it is in contact with; hence, the cell can
regulate itself to secrete the chemical compounds along preferred
directions in such a way the chemicals will most probably follow an
autocrine pathway or a paracrine one. Nevertheless, these cellular
behaviours and this level of detail are unknown and unavailable
for the TGF -b signaling.
On the other hand, it is important to stress that, if all the cells
have similar behaviours in respect to the TGF -b secretion/
absorption, and they are homogeneously distributed, then the
average paracrine signaling to and from other cells cancel out one
another. In the case proposed here, the paracrine signaling inward
and toward the neighbour cells do not cancel out because cells
with different phenotypes do not behave in the same way. To
overcome such difficulty, we propose to subdivide the space where
cells are placed by adopting a ‘‘cell-centric’’ point of view.
Therefore, for each cell, we consider a spheric volume containing
and centred on the cell itself. The surface of the cell membrane
divides this volume between the intracellular part and the external
part. The latter is divided in the extracellular region, which is the
closest neighbourhood just around the surface of the cell
membrane where the TGF -b produced by the cell is released
and can bind with the receptors of the specific cell at the centre of
the volume, and the diffusive region representing the farthest part
of the spherical volume from the cell where the TGF -b cannot
reach the receptors on the cell surface of any cell. Between two
nearest cells, the farthest parts of the respective diffusive regions
are the intangible frontiers where the two ‘‘cell-centric’’ spatial
subdivisions join together. Furthermore, we extend the previous
definition by considering the diffusive region of each cell as the
place where all surround ‘‘cell-centric’’ spaces join together;
therefore, the diffusive region is the common area between a cell
and all its nearest neighbour cells. The TGF -b entering in the
diffusive region loses the possibility to bind with cells and also loses
any dependency on the cell from whom it has been produced. In
other words, the TGF -b produced by the cells, which does not
bind autocrinely, flows before into the diffusive region and then
flows back toward all the cells in the neighbourhood indistinctly, so
that it can bind in a paracrine way.
The portion of volume occupied by the union of all the external
parts depends on the volume of the cells and the distances between
their membranes. This intercellular space is filled with the
extracellular matrix (ECM), a fibrous mesh which gives it the
peculiar behaviours of the porous media. The ECM is responsible
for the reduced diffusivity of the active TGF -b. As a consequence,
the TGF -b in the diffusive region cannot easily diffuse toward the
cells, and the TGF -b in the proximity of the cells is more easily
conveyed toward the receptors on the cell surface. The
prolongated time of diffusion is also responsible for the dispersion
of TGF -b. The obstructions in the porous media introduce non-
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linearity in the diffusion equation. Excessive non-porosity can
forbid the diffusion of molecules through the media, or it will
oblige molecules to follow highly crooked paths. To avoid
excessive complications in the diffusion of TGF -b due to the
complex geometry produced by the disposition of the fibrous
mesh, we can take into consideration the averaged conformational
characteristics of the ECM in the diffusive region by using an
effective diffusion coefficient which can be experimentally
measured. Furthermore, the compartmental description of the
ECM as a region with impaired diffusivity also reproduces the
function of storing growing factors.
Using the first Fick’s law [18], the flux of molecules of TGF -b
crossing a unitary orthogonal surface is given by
J~{DeffLx(b=Vdf ) where the effective diffusion coefficient Deff
includes the porosity of the ECM, and the density of TGF -b is
expressed as the quantity of molecules over the diffusive region
volume Vdf . Discretizing the first Fick’s law and multiplying both
sides of the equation by the orthogonal surface Adf crossed by the
TGF -b during the diffusion between the extracellular region and
the diffusive region, we get JAdf~{DeffAdf=Vdf|Db=Dx where
Vdf=Adf&Dx~10nm is the distance between two adherent cells
whose neighbouring membranes are bridged by E-cad. The
quantity of molecules escaping through the orthogonal surface per
unit of time can also be expressed in terms of the paracrine rate
JAdf~{rpcDb and hence, the TGF -b paracrine rate is equal to
Deff=Dx
2.
We want to remark that the introduction of the diffusive region
makes it possible to mimic the paracriny between cells, but at the
same time, we completely disregard the relative disposition
between cells. Such approximation is not entirely appropriate to
describe the exchange of TGF -b between two specific cells.
However, it is justifiable when describing an averaged effective
exchange of TGF -b between different groups/types of cells.
After the TGF -b binds with the receptors, a series of reactions
involving the Smad proteins follow their internalization. For the
sake of simplicity, we do a model order reduction on the
intracellular model proposed in [14] by considering the non-
phosphorylated Smad proteins in the cytoplasm constant in time,
see last equation in the continuous line box and first equation in
the dashed line box of the system of equations (1).
Due to the importance of TGF -b for different aspects of the
cellular life cycle, degradation of TGF -b in the intracellular
compartment can not be neglected especially in healthy cells
where the over-accumulation of TGF -b can produce a large
disregulation. Therefore, we consider that healthy cells ubiquiti-
nate part of its TGF -b, while mutated cells do not perform such
activity. The set of partial differential equations for the cellular
model are:
Lt bec(w,t)~rsyn b
?
sM(w){bec(w,t)
 
{
rb bec(w,t) Rec(w,t)zrpc
bdf (t)PW
Q~0 r(Q,t)
{bec(w,t)
" #
,
ð2Þ
Lt Rec(w,t)~rsyn RsM(w){Rec(w,t)½ {rb bec(w,t) Rec(w,t), ð3Þ
Lt R?ec(w,t)~rb bec(w,t) Rec(w,t){ rsgnzdw,0 ru
 
R?ec(w,t), ð4Þ
The system of equations (2–5) defines the evolution in time of the
TGF -b produced (bec), its receptor on the cell membrane (Rec), the
internalised TGF -b (R?ec) and the TGF -b in the diffusive region
(bdf ), see Table (1). While the TGF -b in the diffusive region
represents the total amount of TGF -b that all the cells in the nearest
neighbourhood are paracrinely exchanging, the other variables are
intended as averages all over the sub-populations of cells with the
same phenotype. Therefore, the quantities bec, Rec and R
?
ec depend
on the phenotype expressed by the index w (and Q). The region of
interest within the tissue where the tumor begins to develop is also
partitioned in sub-populations of cells, r, identified by the
phenotype index which goes from 0 to a maximum value W. The
phenotype index is associated with the cell aggressiveness and
sensibility to the TGF -b so that w~0 corresponds to the healthy
cells and as w increases, the more cells are aggressive and need more
TGF -b in order to respond to its signal.
In equation (2), the first two terms describe the synthesis of TGF -b
that is secreted in the external region where it is activated and the
binding between the TGF -b and its receptor. The third term takes
into account the averaged values of TGF -b transferred by one cell
with phenotype w toward to the diffusive region and the mean TGF -
b per cell received from the diffusive region. Similarly, equation (3)
describes the synthesis of TGF -b receptors which are displaced on
the cell membrane and binds with the TGF -b present in the
extracellular region. The TGF -b binds to its receptor on the
cytoplasmmembrane, and it is internalized. Inside the cell, theTGF -
b interacts with the Smad [14] at rate rsgn, and to avoid an excessive
abundance of this protein, ubiquitination occurs with rate ru, see
equation (4). The operator di,j in equation (4) is a delta of Kronecker
which takes value 1 when the indexes i~j and zero when the two
indexes are different. The variation of total TGF -b in the diffusive
region is due to the incoming TGF -b which each cell exchanges
paracrinely and the out coming flux shared among all the nearest
neighbour cells, first and second term in equation (5) respectively.
We have used the TGF -b and TGF -b receptors gene expression
data in the cellular model equations (2–5) to evaluate the
respective synthesized quantities and the concentration of the
active TGF -b in the intracellular compartment for each sub-
population with phenotype index in the range ½0,W. In Figure (2),
we show the results for different TGF -b isoforms. Due to the
disregulations of TGF -b production in cells with driver mutations,
we can observe that the concentration values of TGF -b fluctuate
between healthy, pre-tumoral and tumoral cellular phenotypes,
and there is no clear trend which follows the severity of the tumor.
On the other hand, some particular cases are characterized by a
monotonic relationship between the populations’ phenotype and
the concentration of the TGF -b quantities, see the Rec for the
isoforms TGFB1I1/TGFBR3, both R?ec and bec for the isoforms
TGFB1/TGFBR2, the R?ec for the isoforms TGFBI/TGFBR2
ð Þ
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Ltbdf (t)~rpc
XW
Q~0
bec(Q,t) r(Q,t){bdf (t)
" #
:                         ð5Þ
and the Rec for the isoforms TGFB3/TGFBR3. These particular
isoforms are useful to identify the tumor cell phenotype. For
example, the expression for the TGFB1I1 receptors, which have
an antitumorigenic effect, decreases with the increase of cellular
aggressiveness.
It is important to stress that the dynamics of the TGF -b pathway
of a sub-population with a specific phenotype described by the
system equations (2–5) depends on the dynamics of the TGF -b of
the other cellular sub-populations in two different ways. The first
one is the paracrine exchange of TGF -b with rate rpc between the
sub-populations expressed in equation (2) and equation (5). The
second way the equations (2–5) are coupled between different
phenotypes with one another is given by the average number of
nearest neighbour cells r(w,t). The former describes a cellular scale
phenomenon, while the latter is a tissue scale phenomenon. Hence,
if the number of cells of the different sub-populations is not constant,
but changes dynamically, then it is necessary to supply the cellular
model with a set of equations for the cellular evolution of the tissue
(see next subsection for the tissue model).
The Tissue Model
Mutations are responsible for the behavioural changes of cells
that, from a healthy state in which they are capable of correctly
sensing and responding to the surrounding signaling, enter to a
mutated state, where the cells cannot self-regulate in response to
the homeostatic signals. Mutations induced by external agents, or
due to the occurrence of casual variations in the DNA’ s
transcription while proliferating, can be easily accumulated during
a cell life or in multiple progenies. Hence, the increasing in the
population number and the survival of mutated cells can obstruct
the tissue integrity and its functional activity well before the cells
acquire a highly malignant phenotype. As previously stated, the
TGF -b signaling has a pivotal role in maintaining homeostasis at
the cellular scale and the functional integrity at the tissue scale.
Indeed, the TGF -b downregulates the cell proliferation, is
responsible for the cell cohesion at high concentration, induces
cell apoptosis [7]. Nevertheless, the anti-tumorigenic mechanisms
provided by the TGF -b, and their effectiveness, depend on the
capability of the cells to properly sense its signal. DNA mutations
(in particular, driver mutations [19]), on one side, can induce
changes in cell phenotype which destabilize the correct cell
functions. The weakening of a cell and loss of its stability are
responsible for the increase of active TGF -b. On the other side,
mutations can produce a resistance of the cell response to the
TGF -b signaling. Cells with these driver mutations can also
acquire the capability to produce a higher concentration of TGF -b
which is required to reach a different homeostatic level without
incurring in apoptosis. Eventually, a cell can always undergo a
mutation resulting in the failure of the anti-tumorigenicity of the
TGF -b and in an inversion of its role, meaning the transformation
of TGF -b from Dr Jekyll to Mr Hyde occurs [8]. In the latter case,
the TGF -b fails in downregulating cell proliferation and inducing
cell apoptosis; while the excessive production of TGF -b becomes
dangerous for the surrounding cells which have not yet acquired
sufficient resistance to the growing factor.
As previously said, cell mutations are random, and each
mutation can induce apoptotic cell resistance to certain signals, or
it can introduce cellular instability and put the cell to death.
Nevertheless, this does not mean there is no relation between
mutations, or that a mutated cell can accumulate mutations and
return to its original state. Indeed, the cell behavioural changes
induced by mutations can be associated to a stage. This cell stage
indicating the results of mutations does not variate continuously,
but, on the contrary, it is characterized by abrupt phenotype
changes. Therefore, mutations make the cell change from one
stage to another with given probabilities, and the presence of
correlations or constraints between mutations oblige the cell each
time to variate its stage going through a small subset of all the
possible mutation states. Indeed, the mutation state of a cell
monotonically increases during its life, producing a progressive
change of its phenotype which from a normal stage goes through a
series of pre-neoplastic steps to a neoplastic phenotypical stage.
On the other hand, not all the occurrences of a mutation imply a
change of the cellular phenotype or a change in the production of
and response to the TGF -b. Furthermore, at each stage, a cell has a
given probability in acquiring a complete resistance to the tumoral
suppressor action of the TGF -b by switching to a phenotype where
theTGF -b becomes a tumoral promoter. To address the differences
between cell tumoral behaviours and cell response to TGF -b, we
introduce a discrete positive variable w that represents the cell
phenotype. The index w subdivides cells into groups which share the
same phenotype without considering the specific mutations
accumulated by each single cell; therefore, each cell in a group
has the same sensibility to the signaling induced by the active TGF -
b bound to the membrane’s receptors and activates the same
amount of TGF -b per unit of time. From a biological point of view,
in our prospective, the values of w has some relativeness with the
hallmarks of cancer [2,3], and from a medical point of view, it may
be related with the diagnostic stage of cancer.
All quantities and characteristics which refer to a particular cell
stage, or mutated cell population, will depend on the phenotype w.
Therefore, normal cells have a phenotype w~0, pre-neoplastic cells
correspond to w~1, tumoral cells are indexed as w~2, and cells with
aggressive tumoral behaviours and strong resistance to TGF -b
inhibiting signaling have phenotype w~W~3, [20,21]. A possibility
of explaining the different responses to TGF -b signaling by cells
with different phenotypes is thinking that a normal healthy cell has
W different mechanisms working in series to regulate the response/
Table 1. List of variables.
variable/unknown symbol initial value
extracellular TGF -b bec {2,2,2,2} [nmol]
receptors on the
membrane
Rec {2,2,2,2} [nmol]
internalized receptor-
ligand
R?ec {1,1,1,1} [nmol]
autocrine TGF -b b?df 0.1 [nmol V
{1
df ]
number of nearest
neighbor cells with
phenotype w
r(w,t) {6,0,0,0} ½V {1neigh 
osteocytes Ocy 900 ½V {1osteon 
osteoclasts Oc 0 ½V {1frac 
lining cells Lng 0 ½S {1frac 
osteoblasts Ob 0 ½S {1frac 
RANKL RANKL 0 ½nmol V {1frac 
BMP BMP 0 ½nmol V {1frac 
CSF CSF 0 ½nmol V {1frac 
BMD BMD 100 ½%
If the variable depends on the phenotype w, then we give a list of values sorted
by increasing order of the phenotype. References and choices for the numerical
values of the initial values are discussed in the data analysis section.
doi:10.1371/journal.pone.0088533.t001
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Figure 2. Table of TGF -b synthesized, TGF -b receptor synthesized and TGF-b internalized for each phenotype w. These values are
obtained from the numerical solution of the cellular model equations (2–5) at time T~10 days. The various types of TGF -b and receptors are
expressed on top of each box. The tumor grades are sorted into increasing order of severity and aggressivity.
doi:10.1371/journal.pone.0088533.g002
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sensing of TGF -b. Therefore, at the beginning, the signal R?ec
entering the cell is amplified to (cR?ec)
a where 0vav1 and c is a
suitable scaling constant. Then, the amplified signal is sent to all the
Wmechanisms and a binary information s[f0,1g, which indicates if
there is an absence or presence of entering TGF -b respectively, is
sent to the first regulating mechanisms in the series. Each
mechanism uses the entering signal to amplify the binary
information s of a factor (cR?ec)
a. After all the W mechanisms are
applied, the outcome (cR?ec)
Wa is compared with the amplified signal
(cR?ec)
a and their ratio is used as an upregulation of the apoptotic
signaling and as a downregulation of the cell proliferation. For a
normal cell (w~0), all the W mechanisms regulating the response of
the TGF -b are functioning, while for the successive phenotype
w~1, there is one mechanism which always fails to function. The
failure of the mechanism results in no contribution to the
amplification of the binary signal. As the phenotype w increases so
does the number of failing mechanisms. When all the mechanisms
which amplify the entering signal are non-functioning due to the
severe mutations like in aggressive tumoral cells, the binary signal s
(non amplified) compared with the entering signal (cR?ec)
aw1
produces a reduction/dumping of the TGF -b signaling. Conse-
quently, the cells respond by increasing the proliferation and
decreasing the apoptosis.
To describe the dynamic evolution of the cell populations for
each phenotype w, we propose a model based on the effectiveness
of the cell response to the TGF -b signaling. To easily describe the
exchange of TGF -b between cells and their phenotypical
evolution, we focus our attention on a small region of healthy
tissue in which cancer cells will form. Precisely, we consider a
volume containing a cell, all its neighbour cells and part of the
empty space inside the mammary duct, see Figure (1). Cells in a
normal mammary duct are regularly arranged in such a way to
form a tubular surface one cell thick. Even when cells start to
present some pre-neoplastic phenotypical behaviours, they con-
tinue to lay on the mono layer duct surface, but with a less regular
arrangement. Therefore, after having set the volume of the region
of interest, we can consequently fix the average maximum number
of cells, Cw~C0~C1~C2, which can lay on the surface of the
mammary duct. On the other hand, neoplastic epithelial cells in
the mammary duct tend to form multi-layers; therefore, the
volume capacity, CW, of this type of cells is bigger than in the other
cases. The average number of cells r(w,t) within the volume of
interest is described by the following equation:
Ltr w,tð Þ~rp wð Þ 1{
PW{1
Q~0 r Q,tð Þ
Cw
 !
r w,tð Þ
cR?ec w,tð Þgp wð Þ
h i
{ra cR
?
ec w,tð Þga wð Þ
h i
r w,tð Þ{rdr w,tð Þ
zrm dw,WpW
XW{1
Q~0
r(Q,t)z(1{dw,W) (1{dw,0) 1{pWð Þr(w{1,t){r(w,t)
 ( )
z(1{dw,0{dw,W)
rmrp(w{1)
a
1{
PW{1
Q~0 r(Q,t)
Cw{1
 !
r(w{1,t)
½cR?ec(w{1,t)gp(w{1)
,
ð6Þ
with the additional condition that r(w,t)~0 for wv0 (the
phenotypes wv0 are set constantly equal to zero, because they
do not have any biological meaning and they can be disregarded).
The first term on the right hand side of equation (6) describes the
proliferation limited by the volume capacity Cw, and downregu-
lated by both the TGF -b entering the cell, R?ec, and the capability
to respond to it, gp(w). The second and third terms express the
cellular death induced by the TGF -b signaling, which also
depends on the phenotype sensing exponent ga(w), and by the cell
instabilities induced by random mutations. The fourth term
describes the changes of phenotypes (the increase of w) as a
consequence of the mutations. The delta of Kronecker shows that
normal cells can only develop anomalous behaviours, and
aggressive cells (w~W) do not change their phenotype. Similarly,
the fifth term describes the occurrence of important mutations and
of phenotype changes during the cell proliferation. We introduce a
upper limit W for the phenotype values because when cells
accumulate to many mutations, they reach a stage of instability
which are inconsistent with both the aggressiveness of the cell
phenotype and the diagnostic stage of cancer. A similar upper limit
used to label the tumoral stage of the cancer cells has been adopted
in [22] as the limit in which cells are prevalently characterized by
an apoptotic regime instead of those characteristic hallmarks
associated to cancer development [2,3].
In Figure (3), we show the numerical solution of the tissue model
coupled with the cellular model. The figure represents the
evolution of the average nearest neighbour cell sub-populations’
densities inside the mammary duct. The occurrence of driver
mutations inducing phenotype variations and the following
disregulation of TGF -b cell production results in an increase of
cell populations with higher phenotype indexes to the detriment of
the healthy cell population, Figure (3.A). In Figure (3.B) and
Figure (3.D), we can see that pre-tumoral cells, having developed
only a partial resistance to TGF -b signaling, proliferate much
slower than cells with aggressive tumoral behaviours. Nevertheless
due to rare occurrences of driver mutations inducing phenotype
changes, the cell population with phenotype w equal to 2 increases
much slower than pre-tumoral cells, Figure (3.C). In Figure (3.D),
the tumoral cell sub-population with phenotype w equal to 3 is
characterized by a long initial part where they are almost zero
followed by a high proliferation phase until the maximum cell
capacity is reached. This shows that, even though TGF -b has lost
its anti-tumorigenic role on aggressive cells by increasing their
proliferation and driver mutations immediately changing the cell
phenotype to the maximum value W can occur at any moment, the
delay with which aggressive tumoral cells form points out that they
are prevalently originated by sub-populations which have already
developed TGF -b resistance more than by healthy cells. Hence
this highlight the strong capability of TGF -b in slowing down the
cancer development by acting on pre-tumoral cells. On the other
hand the steep increase of aggressive cancer cells, after the first
plateau-like phase, remarks the role of TGF -b as cancer promoter
on aggressive tumoral cells.
It is important to point out that both the cellular model and the
tissue model describe the dynamic of averaged quantities. Also the
coupling between the two is regulated by the average of the TGF -
b entering the epithelial cells and the average numbers of
neighbour cells with a specific phenotype which compose the
mammary duct tissue in the region of interest. The differences in
the order of magnitude between the rates in the cellular model
with respect to tissue model, see Table (2), allow us to overcome
such difficulties; in fact, phenomena occurring at the cellular scale
are much faster and relax to a steady state more rapidly than the
events happening at the tissue scale. Hence the difference between
the two time scales and the loosely coupling, due to averaged
TGF -b quantities, makes it possible to reduce the coupling
between the extracellular and the tissue scales resulting in multi
scale model consistent with the biological phenomena.
Different factors play a role in the prediction of cancer
evolution. The presence of characteristic time scales in the
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development and the dynamics of breast cancer is not so easy to
define or to detect. Nevertheless, few considerations can be made.
Observing the values of the parameters of the multi scale model,
some of which are given in the literature and others are chosen so
that their order of magnitude is consistent with the range of values
present in similar biological situations (see Sec. Methods), one can
a posteriori pinpoint that there are two distinct time scales. The
first describes processes occurring at intra-extra cellular time scale
and the other, at tissue time scale. Hence, the differences between
the two time scales reflect the velocities at which the processes
happen at both the cellular level and the tissue level. This implies
that fluctuations due to various cells activities, even when they are
large, rapidly decay and cancel out. From the tissue scale point of
view, we can disregard large rapid cell variations, and conse-
quently, a posteriori, we are justified in adopting the mean-field
form of interaction between the cell and the tissue scales.
Looking at various clinical cases and at their respective gene
expressions, these two time scales cannot be explicitly determined
due to the lack or impossibility of direct experimental measure-
ments. On one hand, using the information for each patient to
adjust the model parameters so to better fit each dynamics of the
disease, we can observe that there are two distinct time scales, even
though they are not unequivocally defined. On the other hand,
these two time scales do not identify different steps of the cancer
development, nor do they represent two different dynamics. They
only express that an abrupt event which suddenly changes the
behaviours in a small group of cells may initiate the disease, but its
effect will be felt at larger scales only at longer times thanks to the
TGF -b which represents the vector of the interaction.
The bone Niche Model and the Effect of TGF -b in Bone
Remodeling
Breast cancer bone metastases are predominantly osteolytic and
accompanied by bone destruction, bone fractures, pain, and
hypercalcemia, causing severe morbidity (bone metastases occur in
about 70% of patients with advanced breast cancer). Comorbidity
addresses the occurrence of different medical conditions or
diseases, usually complex and often chronic ones, in the same
patient. There is a causal effect, and the bone is a unique
microenvironment in which breast cancer thrives [23]. Bone is
continuously being formed by osteoblasts and resorbed by
osteoclasts, not only to maintain mineral homeostasis but also to
cope with the microfractures that occur naturally [24–27]. We
believe that computational modeling could be very effective in
shedding a light across the intrinsic difficulties of integrating
evidence obtained from experiments and observations spanning
different scales of time and space. There is a growing number of
mathematical and computational models investigating the com-
plexity of this dynamics [28–34] and the interaction with cancer
cells [35,36]. In the adult skeleton, TGF -b is abundant in the bone
matrix, where is released following the initiation of resorption
TGF -b is released from bone matrix [6,37,38]. Few recent studies
have highlighted the complexity of breast cancer metastasis in
bone microenvironment [6,9,39,40]. Although TGF -b enhances
the recruitment and proliferation of osteoblast progenitors, TGF -b
potently inhibits later phases of osteoblast differentiation and
Figure 3. Evolution in time of the average sub-populations’
densities. Given a volume Vneigh of a size equal to the average volume
that, in a healthy mammary duct tissue, contains exactly a cell and all its
nearest neighbour cells arranged on one layer, the densities for each
sub-population in the volume Vneigh is shown. Starting from the top, A)
the healthy cells, B) the pre-neoplastic cells, C) the tumoral cells and, D)
the aggressive tumoral cells are graphed respectively. On the abscissa
the time in months.
doi:10.1371/journal.pone.0088533.g003
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maturation and suppresses matrix mineralization [41–45]. Oste-
oblasts are derived from mesenchymal stem cells and their primary
function is to synthesize the organic collagenous matrix and
orchestrate its mineralization by producing bone matrix proteins
including osteocalcin, osteopontin and bone sialoprotein, and
providing optimal environmental conditions for crystal formation.
Fully differentiated osteoblasts that are surrounded by mineralized
bone tissue are called osteocytes and act as mechanosensors in
bone tissue. They are the most numerous cells within the bone
tissue and scattered evenly through the matrix. With their
flattened morphology and long processes, they form a sensory
network which allows the detection of abnormal strain situations
such as generated by microcracks. Osteocytes are connected to
one another and to surface osteoblasts (bone lining cells) via gap
junctions. Osteocytes secrete sclerostin which is a master switch to
prevent the body from making too much bone. The tuning of
sclerostin allows osteocytes to control the osteoblast’s activity in
bone formation. Under physiological mechanical stimuli osteo-
cytes prevent osteoclast’s bone resorption by changing the
RANKL/osteoprotegerin (OPG) ratio. By communicating these
signals to bone lining cells (the second terminally differentiated
osteoblast cell type) or secrete factors that recruit osteoclasts,
osteocytes initiate the repair of damaged bone. We described a
model of the interplay between osteocytes, osteoblasts and
osteoclasts. This model focuses on the release of TGFb during
resorption phases. Pathological conditions can alter the equilibri-
um between bone resorption and bone formation. Often,
disregulations favouring osteoclastogenesis; osteoporosis is an
example of negative remodelling: the resorption process prevails
on the formation one and this reduces bone density, so increasing
the risk of spontaneous fractures. Here we model the release of the
TGF -b from the bone matrix upon the action of the osteoclasts
which favour the breast cancer metastasis and the unbalance of the
bone dynamics. While experimental works represent primary
sources of parameter values [46], the mathematical and compu-
tational recent works, such as [28–30,32], provide a valuable
validation and discussion of the range of parameters value. Here
we have used parameters values accepted by various literature.
There is a growing use of omics genome wide analysis, see [47]
among others. In our work we have estimated some parameters
from gene expression data. It has been pointed that the difference
between an approximate and exact model is usually remarkably
smaller than the difference between the exact model and the real
biological process [48]. Taking into account the recent experimental
results on the central role of osteocytes [24] and the most recent
mathematical models, in particular Pivonka [43] we have developed
the following conceptual model: first we stress the importance of the
osteoblasts forming the lining of cells attached to the bone tissue. It is
likely they are in communication with the osteocytes in the bones via
a network of canaliculi. When osteocytes die because of fracture
there is a loss of communication of the lining osteoblasts with the
osteocytes. This happens together with a release of RANKL which
is a signal for osteoclasts to arrive and it is a differentiation signal for
the osteoblast which may take sometime to happen. We have
modeled this delay by using a delay differential equation. The
osteoclasts will carry on a resorption of the bone which could be
stopped by decrease of RANKL or by the release of TGF -b by the
bone. Then the osteoblasts with start deploying bone material and
proteins and complete the differentiation process by rebuilding the
network of canaliculum processes. One can think that cancer cells
would take the advantage of absorbing part of the TGF -b so
decreasing the apoptotic probability of the osteoclasts. We have
used DDE to implement both the differentiation lapse of the
osteoblasts. Delays not only are an explicit representation of the
time necessary for spatial transfer of information, but are important
also to take into account the presence of other reactions which are
not explicitly expressed, or included and the lapse of time for them
to happen. The osteoblasts during the bone resorption and bone
formation appears in three forms: uncommitted osteoblasts, pre-
osteoblasts and active osteoblasts. The differentiation from the first
type and the second is accelerated by the presence of TGF -b and
the differentiation from the second type to the third is inhibited by
the TGF -b. Uncommitted osteoblasts lay on the surface of the bone
vessel and their differentiation process is influenced by the
osteoclasts’ resorption activity which is mainly triggered by bone
fracture (and microfracture). This event propagates and after an
average time t0 uncommitted osteoblasts begin to differentiate. The
presence of TGF -b can be of help for their differentiation, or even
necessary, but the TGF -b cannot abbreviate it because it does not
speed up the travel of information. On the other hand TGF-b can
delay the activation of osteoblasts. The complete and complex
differentiation process of the osteoblasts can be summarized from
the first stage to the last stage by packing all the complexity of the
process inside a delay ttot(b)~t0ztdiff (b) dependent on the TGF -
b, b. The delay tdiff (b) must be positive and finite, because the
TGF -b does not preclude the osteoblast activation and second
important factor to remark is that the effect of TGF -b on the
osteoblasts is local (at contact) in space and picked (rapid effect and
defined delay ) in time. On the other hand the diffusion of TGF -b,
osteoblasts and their concentration are much more sensible to space
inhomogeneities and large time distributed events. Our DDEmodel
equations are listed below:
Lt Oc~rOc RANKL(t):CSF (t){aOc Oc(t), ð8Þ
Lt Lng~pLng BMP(t){mLng BMP(t{t(b))
{aLng Lng(t),
ð9Þ
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Lt Ocy~fOcy Ob(t){aOcy H(t) H(1{t),                           ð7Þ
Lt Ob~mLng BMP(t{t(b)){nfOcy Ob(t){aOb Ob(t),  ð10Þ
Lt RANKL~pRKL Ocy{Ocy(t)
 
H(t) H(1{t)
zrRKL Ob(t){dRKL
ð11Þ
RANKL,
Lt BMP~pBMP Ocy{Ocy(t)
 
{dBMP BMP(t),         ð12Þ
Table 2. List of parameters.
parameter symbol value
gene expression of the TGF-b bsM(w) {–1.853, 1.724, 1.614, 1.669} [nmol]
gene expression of the receptors RsM(w) {–7.47, 6.713, 5.017, 4.128} [nmol]
rate of synthesis rsyn 133.333 [s
21]
Smad signaling rate rsgn 0.003018 [s
21]
paracrine rate rpc 10 [s
21]
binding rate rb 0.0074 [nmol
21 s21]
ubiquitination rate ru 0.007 [s
21]
total number of phenotypes
and malignant phenotype
W 3
proliferation rate rp(w) {–1.610
26, 1.61026, 1.61026, 1.61026} [s21]
apoptosis rate ra 9.610
28 [s21]
degradation rate rd 1.610
28 [s21]
mutation rate rm 1.610
214 [s21]
cell capacities Cø {–6, 6, 6, 8} [Vneigh
21]
dimensional constant a 1 [s21]
dimensional constant c 1 [nmol21]
Osteocytes formation rate fOcy 0.00032 [Sfrac Vosteon
21 day21]
Osteocytes apoptosis rate aOcy aOcy 30 [Vosteon
21 day21]
Osteoclasts recruitment rate rOc 0.8 [Vfrac nmol
22 day21]
Osteoclasts apoptosis rate aOc 0.0625 [day
21]
Lining cells proliferation rate pLng 50 [mm nmol21 day21]
Lining cells maturation rate mLng 50 [mm nmol21 day21]
Lining cells apoptosis rate aLng 0.1525 [day
21]
Osteoblasts apoptosis rate aOb 0.1525 [day
21]
RANKL production (Osteocytes) pRKL 300 [nmol Vosteon Vfrac
21 day21]
RANKL production (osteoblasts) rRKL 2.5 [nmol Sfrac Vfrac
21 day21]
RANKL degradation rate dRKL 8.6643 [day
21]
BMP production rate pBMP 1 [nmol Vosteon Vfrac
21 day21]
BMP degradation rate dBMP 8.6643 [day
21]
CSF production rate pCSF 0.1 [nmol Vosteon Vfrac
21 day21]
CSF degradation rate dCSF 69.3147 [day
21]
Bone resorption rate rbn 9.4610
24 [Vfrac nmol
21 day21]
Bone formation rate fbn 5.9098610
26 [Sfrac nmol
21 day21]
TGF-b extraction rate rb 2.2610
210 [nmol day21]
TGF-b degradation rate db 0.1189 [day
21]
Number of cancer cells Nc 2000
Constant time delay T 0 6.02 [day]
Constant time delay D 22.36 [day]
Maximum amount of osteocytes Ocy Ocy 900 [Vosteon
21]
Minimum effective amount of TGF-b inducing delay b 861028 [nmol Vfrac
21]
Burried osteoblast factor n 1 [Vosteon Vfrac
21]
If the parameter depends on the phenotype w, then we give a list of values sorted by increasing order of the phenotype. References and choices for the numerical
values of the parameters are discussed in the data analysis section.
doi:10.1371/journal.pone.0088533.t002
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probability of malignant mutation pW 5.610
27
proliferation exponent gp(w)                                                                     {–0.12, 0.06, 0.,20.06}
apoptosis exponent                                                     ga(w)                                                                    {–0.12, 0.06, 0.,20.06}
Lt CSF~pCSF Ocy{Ocy(t)
 
{dCSF CSF (t), ð13Þ
Lt BMD~fbn Ob(t){rbn Oc(t), ð14Þ
Ltb~rb Oc(t){db b(t){Nc rpc b(t), ð15Þ
t(b)~t0zD
b
b(t)zb
: ð16Þ
The equation (7) describes that a microfracture occurring at
t = 0, is sensed by osteocytes that undergo apoptosis which ends in
about one day [46,49]. In equation (8) the osteoclasts are recruited
to the BMU in response to a combination of RANKL and CSF,
and die at a rate aOc; The equation (9) shows that immature
osteoblasts are recruited in response to TGF -b here represented as
BMP, and differentiate into mature osteoblasts after 20 days.
Mature osteoblasts can either self-bury with a rate nfOcy and
differentiate into osteocytes at rate fOcy or die at rate aOb, see
equation (10). References could be found in [46]. The equation
(11) describes that surviving osteocytes secrete RANKL at a rate
proportional to the ‘‘size of the fracture’’ i.e. number of osteocytes
that underwent apoptosis; osteoblasts produce both RANKL and
OPG at rates dependent on their maturity and with characteristic
delay [36]. The equations (12, 13) describe that BMP and CSF are
secreted by osteocytes in response to the microfracture damage.
Both chemicals decay, but CSF is also depleted by osteoclasts;
representing the idea that CSF is a chemoattractant and the
osteoclasts move on when its concentration becomes low [50,51].
Note that TGF -b and bone morphogenetic protein (BMP) have
often opposite behaviour. In a hair follicle stem cell niche BMP
signaling maintains stem cell quiescence while TGF -b stimulates
stem cells both in vivo and in vitro and antagonizes repressive
BMP signaling [52].
The equation (14) follows [28] equation where bone is rebuilt at
rate fbn by mature osteoblasts and resorbed at rate rbn by
osteoclasts. The equation (15) describes the TGF -b from the
resorption action of the osteoclasts.
In Figure (4) we show the simulated results of the ODE model:
Bone density (A, B), number of osteoblasts (C, D), number of
osteoclasts (E, F) and TGF -b (G, H) compared between control (A,
C, E, G) and cancer condition (B, D, F, H). Results show a
negative remodelling balance in the cancer case. The values in
Figure (4) are expressed in terms of averaged quantities which are
the osteon volume, the fracture volume and the fracture surface.
Considering a microfracture of 1mm width which caused the
damage of a number of osteocytes 30 times smaller than the
number of osteocytes in the osteon, the relation between them are
Vosteon^30Vfrac and Vfrac^Sfrac:1mm, see [53].
The negative balance of the bone density matrix due to the
effect of cancer cells in the bone niche, where metastasis occurs, is
strongly depending on the number of cancer cells. Even though
breast cancer cells find in the bone tissue a richer environment of
TGF -b favouring their proliferation, the formation of metastasis is
not a very easy and probable event. Different biological defensive
systems and causes concur to avoid the formation of metastasis.
Nevertheless maybe due to the high number of breast cancer cells
detaching from the main tumor and reaching the bone tissue
though the vascular system, or maybe due to the occurrence of the
rare event in which all the metastatic defensive systems fail, few
cancer cells (not necessarily in positions close one another -
information neglected in the models proposed) initiate the
metastasis. In the very initial development stage, the few metastatic
cells do not really affect the bone system. On the other hand, at
this stage, a microfracture and the successive remodeling process
proceed faster than the increasing of the local cancer cell
population. In the early stages of metastasis formation process,
we assume that during the remodeling process, the number of the
tumoral cells in the bone niche is constant, but after successive
microfracture, due to the abundance of TGF -b, the cancer cell
population increases. The more cancer cells increase the more
they affect the bone remodeling process. When cancer cells
increase in number, on one side, they increase the time of
maturation of lining cells into osteoblasts through the action of
TGF -b on the BMP, on the other side, they obstruct the tissue re-
mineralization. The result is a weaker and less dense bone.
he TGF -b is responsible for the delay in the maturation of
osteoblasts. An excessive quantity of TGF -b released during the
bone remodeling process is the cause of the reduction of the bone
density. In the same way, a reduced quantity of TGF -b induces a
rapid maturation of osteoblasts. This prevents osteoclats resorption
in the BMU causing a local increase of bone mass with less
structural strength.
Absence of a spatial representation of the bone niche does not
allow us to completely describe the dishomogeneities in the bone
mineral density caused by the cancer cells in bone tissue which are
known as mixed lesions. Cell-to-cell spatial interactions like
volume exclusion and chemotaxis are necessary to reproduce
mixed lesions. In order to mimic the presence of mixed lesions, we
can use our model to simulate the occurrence of multiple fractures
in which the intensity of the released TGF -b fluctuates randomly.
The variability of the bone density accumulated at the end of each
remodeling by spatially independent BMUs can be considered as
an index for mixed lesions. Hence, high variability will be an
indication of mixed lesions, while low variability will represent the
cases of osteolytic or osteoblastic lesions depending on negative or
positive changes of the averaged bone density, respectively.
Nevertheless, such variability is related to the probability
distribution used for the intensity of the released TGF -b.
In Figure (4), we show the evolution of the bone remodeling
process after a small fracture when the population of cancer cells
in the bone niche is of the order of 103. This is sufficient to see that
in the local region of bone in which metastasis is developing, the
bone density matrix decreases of 1%. The bone mineral density
represents a marker to identify the development of metastasis and
its effectiveness is based on the causal relation or on comorbidity
between breast cancer and osteoporosis.
Discussion
We have developed a mathematical model describing the multi
scalar behaviours of the TGF -b, first by representing the actions of
the behaviours of the TGF -b from the intracellular to the
extracellular scale using a cellular model which is based on the
results of the work published by Laise et al. for epithelial-
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mesenchymal transformation [14] and which also addresses the
important aspect of autocrine/paracrine signaling induced by
the protein. Then we have further developed the model to
investigate the extracellular mechanisms of action of TGF -b at
larger scale and its involvement in cancer. This has led to a
tissue model of breast cancer, which usually metastasise to the
bone tissue. Therefore, we have also studied the relation between
the metastatic cell, the bone tissue and the TGF -b. We have
identified the TGF -b as one key molecule involved in cancer
because it is antioncogenic and pro-apoptotic at low concentration
and pro-tumorigenic at high concentration due to its mechan-
obiology properties through the interaction with the cytoskeleton
and with the extracellular integrins/E-cad proteins. This multi
scale model is based on a multi scale multifunction molecule, in
other words it is a sort of hub for apoptosis signaling at one scale
and for the cytoskeleton function and cell-to-cell interaction at
another scale.
Our work has focused in generating and connecting three
models: one cellular model (intracellular and extracellular TGF -b)
and two tissue models (the breast cancer in the mammary duct and
the bone tissue). Each of these models refers to a specific level of
organization, and hence it is possible to approximately associate
each of them to a specific length scale. Such spatial subdivision of
the models is also reinforced by their temporal subdivision in the
dynamic processes (cell/tissue scales) and in the cancer disease
progress (breast/bone tissues). The differences in temporal scales
of the various processes described in these models hamper the
aggregation of all these models into a single one. Indeed, the time
scales of TGF -b inside the cell are usually much shorter than
events at the tissue level. This has been resolved by considering
that the variables at the cellular level are passed as ‘‘averages’’ to
the tissue level. The information related to the spatial positioning
of cells in the tissue has been neglected in order to find results not
dependent on the tissue geometry. In other words, we do not
consider cellular specialisation in the tissue; therefore, cellular
parameters are space and cell type independent, but, if necessary,
only phenotype dependent. In this way we avoid an increase in
the number of degrees of freedom; furthermore, our approach
leads to a model order reduction with no bias for the position of
the cell.
The TGF -b has been reported to show an autocrine control
system to inhibit cell replication, thus maintaining the tissue
cell homeostasis. We have modeled the process that, following
mutations, drives the inhibition into cell cycle progression. So
the cell increases the autocriny i.e. the production and endocytosis
of TGF -b in order to regulate the cell cycle progression, but this
results in an increase of tumorigenicity; meanwhile, the TGF -b
also acts in disrupting the actin cytoskeleton which disrupts
the actin and E-cad anchorage; hence, the cell contracts and,
as consequence, this increases the activation of extracellular TGF -
b; therefore the cell without contact inhibition starts replicating
actively. The end of this is a high replication rate of cancer cells
that needs to produce TGF -b to sustain such growth rate.
In our opinion the downregulation of the TGF -b from the
internalized TGF -b has a defensive effect because it helps to
reduce the internalization of TGF -b [54]. In the bone niche, bone
and cartilage contain large amounts of TGF -b and target cells for
TGF -b activity. The autocrine and paracrine stimulation by TGF -
b is important for osteoblasts differentiation. The TGF -b
promotes osteoblast differentiation and the TGF -b from the
osteocytes in the bone make them lining up to the bone. In case of
fracture the osteocytes secrete RANKL which activates the
osteoclasts. The demolition of the bone around the fracture frees
lot of TGF -b which further attracts the osteoclasts but in the long
term induces apoptosis.
The model proposed suggests an ecological perspective of the
cancer. Cancer cell changes are associated with alterations in the
mechanical properties of the microenvironment; as tumor expands
there is an increase in tissue compression and interstitial pressure,
generating cell and tissue tension within the confined stroma.
These forces induce the release and activation of various growth
factors and subsequent changes of the contractility and viscoelas-
ticity of tumor cells. In breast cancer, the different stages of cancer
cell determine different mechanical interaction with basement
membrane (BM) architecture and ECM. TGF -b plays a key role
in orchestrating the cell-ECM tension. A hyperplasia lesion
typically involves the loss of normal cell polarization and
organization, the changes in cell-cell contacts and cell-ECM
interactions, which result in altered cellular tension and mechano-
sensing and transduction. In carcinoma in situ lesions, cell polarity
is lost and the lumen is filled by cells. This volume expansion and
resistance from the BM and interstitial ECM lead to increased
mechanical forces between tumor cells and the stromal matrix.
Simultaneously, ECM components are abnormally deposited and
remodeled, which results in increased ECM and tissue stiffness,
and in turn, cell generated tension. In invasive lesions, tumor cells
break down the BM and invade into the interstitial ECM. The
reciprocal forces between tumor cells and the ECM continuously
increase. The abnormal deposition and remodeling of ECM
collagen further increase ECM and tissue stiffness. Tumor cells
generate greater tension in response to this increased mechanical
stimulation. As tumor cells invade through the BM and ECM, they
experience a range of different forces from the dense ECM
network.
Although TGF -b is a growth inhibitor for most epithelial cells, it
has multiple and often opposing effects depending on the tissue
and the type of cells. Why TGF -b is not regulated more tightly?
We believe that cancer is a disease related to the ageing; it is still
very rare in young and mature organisms, while is very common in
the elderly; so there is no great selection feedback and cancer is a
mean to send in apoptosis an aged organism when most of the cells
have accumulated mutations, so in some analogy it has the same
role that TGF -b has with single cells when energy becomes
limited.
Methods
We have considered parameter estimates from experiments
reported in literature and from published mathematical and
computational models. Furthermore, some parameters are explic-
itly obtained from gene expression analysis, while some other are
derived from the models so that their estimation as well as the
models’ outputs remain inside ranges of validity consistent with the
biological phenomena. The values of the parameters and the
Figure 4. Bone remodelling process. Evolution in time of the bone density (A,B), the osteocytes (C,D), the osteoclasts (E,F), the osteoblasts (G,H),
and the TGF -b in the bone niche released during the resorption (I,J). Control (first column) versus cancer condition (second column) is shown. The
bone densities are expressed in percentage, the osteocytes are in number of cells per osteon volume (Vosteon), the osteoblasts are in number of cells
per fracture surface (Sfrac), the osteoclast are in number of cells per fracture volume and the TGF -b in nanomoles per fracture volume. On the
abscissa the time is in days.
doi:10.1371/journal.pone.0088533.g004
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boundary conditions for the ODEs and DDEs used in the
numerical simulations of the models are given in Tables (1, 2).
In the cellular model, the values for the amount of the various
isoforms of TGF -b and receptors are extracted from gene
expression data. In the specific case shown in Figure (3) and
Table (2), where the cellular model and the tissue model are
coupled together, we have considered the TGFB2 and TGFR3
isoforms for the cytokine and its receptor respectively.
The TGF -b paracrine rate is derived as a direct consequence of
the first Fick’s law with an effective diffusion coefficient that takes
into consideration the effects of the ECM. The order of magnitude
for rpc is estimated from the data in [55–58] relative to a healthy
mammary epithelial cell. The reduction of volume in cancer
mammary epithelial cells, as highlighted in [56], is the sign of cell
cytoskeletal instabilities due to mutations. As consequence of the
cell contractions, a small empty volume, which we have named
diffusive region, appears between the cancer cell and the nearest
cells of the tissue. The relation between the diffusive region volume
and the neighbour volume is Vneigh&7(VcellzVdf ) and Vcell is the
averaged volume of a healthy mammary epithelial cell [56]. For
the numerical values of rsyn linking the production of TGF -b to
their gene expression, of the TGF -b signaling rate to initiate the
reactions with the Smad proteins in the cytoplasm and of the
TGF -b binding rate occurring at the cell surface, we refer to the
experimental results in [16] with the assumption that Smad
concentrations remain constant. The order of magnitude of
mammary epithelial cell proliferation rate is based on the data
reported in [59,60]. For the tissue model, the mutation rate and
the probability, pW, that a mammary cell undergoes malignant
mutation showing a strong resistance to TGF -b apoptotic
signaling, are extracted from [21]. Based on the works [20,21],
we have estimated the proliferation and the apoptosis exponents
such that the local cell sub-population with highly malignant
phenotype (w~3) reaches the 10% of the local collective cell
population approximatively after 2 years and the cell with
phenotype w~2 represents those cells with sufficient driver
mutations so that the signaling induced by the TGF -b begin to
change from anti-tumorigenic to pro-tumorigenic. Most of the
parameters used in the bone niche model are taken from the
following works: [47,53,61]. For the time immature osteoblasts
take to differentiate into mature osteoblasts, the rate of osteocytes
formation, the apoptosis rate of the osteoblasts and the rate at
which the RANKL is released by the osteoblasts, we refer to the
results in [46,62]. For the quantity of TGF -b stored in the bone,
we refer to the work of Janssens [63].
Gene Expression Data
Despite the wealth of molecular data (such as sequence and
gene expression data) and physiological and pathological data
from different populations, there is a lack of cell abundance
estimate in the different tissues. Therefore we extracted informa-
tion from gene expression data. Gene expression patterns supply
insight into complex biological networks. Gene expression
profiling of the tumor microenvironment during breast cancer
progression distinguishes breast carcinomas from normal breast
tissues. We have re-analysed several gene expression data related
to breast cancer dynamics from the Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/); after an exploratory analysis
and literature analysis, we focused on the following datasets:
(accession numbers): GSE14548, GSE33450 and GSE8977. These
datasets originate from experimental design on early stages breast
cancer progression and tumor microenvironment. Normalization
procedures and statistical analysis are performed by using
Bioconductor R packages [64]; the background correction and
normalization is performed by using PLIER algorithm. PLIER
algorithm produces an improved gene expression value [65] as
compared to the other algorithms. It accomplishes this by
incorporating experimental observations of feature behaviour
Specifically, it uses a probe affinity parameter, which represents
the strength of a signal produced at a specific concentration for a
given probe. The probe affinities are calculated using data across
arrays. The Bioconductor package limma was also used to
calculate average expression levels, log fold changes and adjusted
p-values for each probe. Standard anova and Box plots
representation were used to analyse and check out visually the
expression levels of these genes for different conditions. We have
used gene expression averaged quantities to better unveil the
functions of the TGF -b in the cancer dynamics; nevertheless, the
model proposed should be used with a pinch of salt. Single patient
gene expression values may not be sufficient to catch the specificity
of the evolution of the disease for each patient and the role of the
TGF -b. Comorbidities, patients’ previous medical conditions and
the exact initial time of breast cancer formation may be unknown,
but they affect the prediction of cancer evolution. We have also
considered Transforming Growth Factor beta 3 (TGFB3) involved
in cell differentiation and which interacts with TGF -b receptor 2
(TGFBR2), a tumor suppressor gene.
Sensitivity Analysis
The correctness of the proposed multi scale model and its
predictive ability on development and progress of the disease
strongly depend on the knowledge of the parameters and the
respective errors; hence, it is important to rightly identify and
estimate the parameters whose the multi scale model is more
sensitive. Using the Local Sensitivity Analysis method (LSA) in
[66], we compute the first order sensitivity indexes for each of the
three models separately. Even though the non-linearity of the
models suggests that the second order sensitivity indexes analysis
could be relevant to identify the most sensitive model’s parameters
couples, for sake of simplicity, we neglect the second order
variance decomposition, and we show the LSA for all single
parameters. The first order sensitivity index Si for a parameter Xi
given the parameters X and the output Y~f (X) is a pure number
defined as Si~V (E(Y jXi))=V (Y ), where E(Y jXi) is the condi-
tional expectation value obtained by sampling all the parameters
X from their prior distributions except Xi which is maintained
constant, V(E(Y jXi)) is the variance of E(Y jXi) due to the
variation of Xi and V (Y ) is the variance due to variation of all the
parameters X.
In the cellular model, the concentration of active TGF -b
present in the extracellular region is strongly sensitive only to those
parameters directly related to their gene expressions, Figure (5.A,
5.B). The same holds true for the TGF -b receptors on the cell
membrane, Figure (5.C, 5.D). Consequently, accurate information
regarding the gene expression are much more important than
other parameters to finely tune the outputs of the model and
reduce the error on the capability of the model to be predictive.
The fact that gene expressions play a fundamental role on the
model is because they appear as terms of source of the proteins.
Indeed, the other parameter that partially influence the model is
the rate of synthesis, which also appears as factor in the source
terms of equations (2, 3). Nevertheless, being the prior of the
parameters uniformly distributed with a variance of 10% of their
values expressed in Table (2), the sensitivity of the system to rsyn is
approximatively two orders of magnitude less than to the gene
expressions. On the other hand, the internalized compound not
only is sensible to the gene expressions of the TGF -b and its
receptors, but also to the possibility cells have to internalize the
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Figure 5. Cellular model LSA. The first order sensitivity index of the cellular model’s parameters for (A,B) the TGF -b, (C,D) the receptors, (E,F) the
TGF -b internalized and (G) active TGF -b in the diffusive region. On the left column the phenotype w~0 and on the right column w~4 with
exception of the TGF -b in the diffusive region (G) which is independent of the phenotype.
doi:10.1371/journal.pone.0088533.g005
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active form of TGF -b through the receptors. In Figure (5.E, 5.F),
we see that the quantity of TGF -b accumulated in the cell
cytoplasm depends on the capability of each specific cellular sub-
population to respond to the TGF -b signaling as well as on the
capability of healthy cells to ubiquitinate the TGF -b. The TGF -b
in the diffusive region depends on how fast it diffuses in the
surrounding space and on its production by the healthy cells,
Figure (5.G). Indeed, we are observing the system, which is in an
out-of-equilibrium condition, at a time when the quantity of
healthy cells is the predominant cell sub-population component of
the total cell population; therefore, in this case, there are no
contradictions in saying that the major sources of TGF -b are the
healthy cells.
The sensitivity analysis for the tissue model presents a more
complex scenario of the relevant parameters affecting the densities
of each cell sub-population based on the cells phenotypes, see
Figure (6). Due to the interaction driven by the paracrine
exchange of TGF -b, the volume exclusion constraints between
the cellular capacities and the strong non-linearity produced by the
different cell capabilities of sensing/responding to the TGF -b, we
see that the dynamical evolution of a cell sub-population with
specific phenotype depends on parameters strictly non-related to
that specific sub-population phenotype. The simplest case is given
by the healthy cell sub-population which is prevalently sensitive to
its proliferation/apoptosis rates, its exponential indexes, and the
healthy cell capacity, Figure (6.A). Depending on the time at which
the system is observed, we can see a more or less dependency of
the healthy system on the proliferation rate of the pre-tumoral
cells. The cell sub-populations characterized by driver mutations
show all the same behaviours of being sensitive to the prolifera-
tion/apoptosis rates and exponential indexes not only of their
same phenotype, but also to those with less aggressive phenotypes,
Figure (6.B, 6.C, 6.D). The small dependency on the parameters
with phenotype w~2 is due to the particular transition role of this
cell sub-population in respect to its response/sensing of the TGF -b
and consequently to the small range of the proliferation/apoptosis
indexes (meaning small variance of the prior distribution adopted
in the LSA). All cell sub-populations do not show any sensitivity on
the capacity C3, exception done for the highly aggressive tumoral
cells which depend on both values of the cell capacities,
Figure (6.D).
From the LSA, Figure (6), we see the emersion of an explicit
pattern on the parameters which reflects the behavioural evolution
of the tissue in terms of dynamics. In fact, even though all the cells
compete for limited room by obstructing or killing the cells with
different phenotypes, the number of tumoral cells and their
survival, during the early stage of cancer, are strongly linked to
their phenotypical ancestors. Hence, the two major sub-systems of
the tissue, healthy tissue and tumor, show the dual behaviour of
two resources competing systems like in the predator-prey model,
on one side and of two shearing TGF -b systems in which one try
to stabilize via TGF -b the other sub-system without any success
because the driver mutations in the aggressive cancer cells have
changed the apoptotic signaling of the TGF -b into a tumor
promoter, on the other side.
The LSA in the bone model shows two groups of variables:
those which are mostly sensitive to the number of osteocytes in the
BMU before a fracture occurs, but do not show any relevant
sensitivity to the TGF -b related parameters, and those variables
which, even though depend on the osteocytes, are sensitive to the
Figure 6. Tissue model LSA. The first order sensitivity index of the tissue model’s parameters for the tissue sub-population: (A) w~0, (B) w~1, (C)
w~2, and (D) w~3.
doi:10.1371/journal.pone.0088533.g006
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delay induced by the TGF -b as well as to the other parameters
responsible to the high concentration of TGF -b in the bone niche,
Figure (7). The number of lining cells depends on the time they
take to differentiate and hence they are sensitive to the TGF -b,
Figure (7.C). On the other hand, mature osteoblasts are not very
sensitive to the TGF -b, but are sensitive to the apoptotic rate of
the lining cells because soon or later all the lining cell, which do
not undergo apoptosis, follow through maturation, Figure (7.D).
We have also observed that the RANKL presents a strong
sensitivity to the TGF -b which is an indication that the small
quantity of RANKL released by the osteoblast compared to that
released by the damaged osteocytes network is important to affect
the dynamics of the bone remodelling, Figure (7.E). Consequently,
the dependence of osteoclasts on TGF -b is due to the RANKL,
Figure (7.B). The mineral bone density is the variable with the
highest sensitivity to the TGF -b, Figure (7.F), showing that the
resorption and remineralization are carefully synchronized by the
TGF -b which regulates the time interval between osteoclasts and
osteoblasts actions.
It is important to highlight that the roles of osteoclasts and
breast cancer cells, in the bone niche, are the same in terms of
TGF -b, but are extremely different in their resultant actions. The
first (osteoclasts) produce TGF -b to induce a delay necessary to
complete the bone resorption and to carefully balance the
maturation of lining cells, but at the same time, they are miners
releasing a strong chemoattractant for the tumoral cells from the
breast lobular duct. The last (breast cancer cells) remaining in the
bone niche because rich of TGF -b, which is a fundamental
resource for their survival, release TGF -b to prolongates the
Figure 7. Bone model LSA. The first order sensitivity indexes of the bone model’s parameters for (A) osteocytes, (B) osteoclasts, (C) lining cells, (D)
osteoblasts, (E) RANKL, and (F) bone mineral density.
doi:10.1371/journal.pone.0088533.g007
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mining of the osteoclasts, to make themselves space and to
maintain their cell cycle progression.
As previously stated the LSA is a useful tool to determine the
importance of the parameters based on the fact that a parameter
of the model with high sensitivity and low variance should be
carefully chosen and/or measured because highly affecting the
outcomes of the model while a parameter with low sensitivity and
high variance does not influence the system dynamics. Further-
more, we have used the LSA to reveal the relationships of and the
patterns of variables depending parameters in the tissue and in the
bone model.
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